Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Ani Pharmaceuticals (ANIP) Asset Writedowns and Impairment (2019 - 2024)

Ani Pharmaceuticals' Asset Writedowns and Impairment history spans 6 years, with the latest figure at $7.6 million for Q4 2024.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to $7.6 million in Q4 2024 year-over-year; TTM through Dec 2025 was $7.6 million, a 0.0% change, with the full-year FY2025 number at $767000.0, down 89.91% from a year prior.
Asset Writedowns and Impairment hit $7.6 million in Q4 2024 for Ani Pharmaceuticals, up from -$1000.0 in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for ANIP hit a ceiling of $7.6 million in Q4 2024 and a floor of -$1000.0 in Q3 2022.
Historically, Asset Writedowns and Impairment has averaged $2.1 million across 4 years, with a median of $341000.0 in 2020.
Biggest five-year swings in Asset Writedowns and Impairment: surged 354.67% in 2020 and later surged 596.19% in 2021.
Tracing ANIP's Asset Writedowns and Impairment over 4 years: stood at $341000.0 in 2020, then surged by 596.19% to $2.4 million in 2021, then crashed by 100.04% to -$1000.0 in 2022, then surged by 760100.0% to $7.6 million in 2024.
Business Quant data shows Asset Writedowns and Impairment for ANIP at $7.6 million in Q4 2024, -$1000.0 in Q3 2022, and $2.4 million in Q4 2021.